New Publication Further Validates Capitainer Technology for Remote Alzheimer’s Disease Biomarker Testing
Stockholm, Sweden, May 2026 – A new publication in Nature Communications demonstrates that remotely self-collected capillary blood samples can be used to measure Alzheimer’s disease biomarkers associated with cognitive decline and function in older adults.
The publication, “Alzheimer’s Disease blood biomarkers measured through remote capillary sampling correlate with cognition in older adults”, builds on previous findings from the DROP-AD study published in Nature Medicine, which demonstrated the feasibility of remote dried blood and plasma sampling for Alzheimer’s disease biomarkers. The new publication further explores the potential of self-collected remote sampling in unsupervised real-world settings. In both studies, blood samples were collected using Capitainer® volumetric microsampling cards.
In the study, participants collected blood samples themselves at home using fingertip sampling devices and returned the samples by post. Researchers found strong correlations between capillary and venous blood biomarkers, while also demonstrating associations with cognition and functional outcomes.
“These publications represent an important step toward making Alzheimer’s disease biomarker testing more accessible and scalable,” says Christopher Aulin, CEO of Capitainer AB. “Alzheimer’s disease is one of the world’s largest healthcare challenges, and blood-based biomarkers are expected to play a central role in future diagnostics, clinical trials, and patient monitoring. Remote sampling technologies have the potential to enable testing at significantly broader scale, extending access beyond traditional clinical settings.”
For more information, please contact:
Christopher Aulin, CEO
Phone: +46 (0)708 977577
Email: christopher.aulin@capitainer.com
About Capitainer
Capitainer AB is a Swedish MedTech company that develops and sells patient-centric solutions for self-sampling of blood, plasma, and urine. Founded in 2016, Capitainer has developed unique technologies for collecting and drying exact volumes of fluid within easy-to-use sampling cards. These cards may be sent as standard post to relevant testing laboratories, thus bypassing the need for cold chain logistics and specialised packaging. Capitainer’s products are market-leading with respect to precision and accuracy, with demonstrated equal performance to established pipetting methods. The products are applicable within several market segments, including but not limited to, clinical biomarkers, therapeutic drug monitoring, genomics, drug abuse and doping testing, and R&D and clinical studies.